In July 2022, our founders discovered how our breakthrough therapies worked by targeting a fundamental vulnerability in cancer cells, killing cancer cells while leaving normal cells intact. Instantly, our paper became one of the most downloaded articles published by prestigious Nature Cancer. journal. Today we are approved to start our Phase I clinical trials with drugs developed from this groundbreaking discovery.
Our therapies work by shutting down protein synthesis in cancer cells, causing catastrophic levels of endoplasmic reticulum stress that lead the cell to death by apoptosis, or programmed cell death. Our first therapy heralds a series of innovations in cancer therapy:
The first therapy to induce sustained and uncompensated endoplasmic reticulum stress causing cell death.
The first targeted agent against LIPA’s role in the endoplasmic reticulum.
The only oral agent with cytotoxic activity against most forms of breast cancer (ER+, ER-, TNBC), and other untreatable cancers including; Ovarian, Pancreatic, Liver and Endometrial.
*These statements are based on preclinical research and have not been evaluated in clinical trials nor by the FDA or any government health agency.
A new hope for patients with metastatic therapy resistant cancers.
0{{current_slide_index}} | 0{{total_slide_count}}
Where to find us
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247
Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247